In the blue corner
Qureight
AI-powered imaging and precision endpoints for clinical trials in lung and heart disease
Biotech United Kingdom
An AI-powered imaging CRO providing enterprise-grade imaging analysis and precision endpoints for clinical trials in lung and heart disease, with automated
About Qureight
Qureight is an AI-powered imaging Contract Research Organization (CRO) that accelerates clinical trial development through data curation and precision endpoints. The company provides enterprise-grade imaging analysis and healthcare data management, specializing in lung and heart disease research, including conditions like Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension, and Bronchiectasis.
The company operates an end-to-end imaging CRO service combining three main offerings: global imaging CRO services with workflow tools for rapid site onboarding and participant evaluation; AI-powered endpoints and analytics using proprietary deep-learning lung image biomarkers (Lung8™, Air8™, Fibr8™, Glass8™ and Vascul8™) for tracking treatment response and predicting disease progression; and data science products including synthetic control arms for clinical trials where placebo arms are impractical or unethical.
Qureight's platform is built on modern, high-performance technology designed for speed, scalability and reliability. The team combines expertise in respiratory medicine, radiology, machine learning, data science, software engineering and clinical operations, based in Cambridge and London, UK. The company maintains ISO 13485:2016 and ISO 27001:2022 certification and ensures GxP and 21 CFR Part 11 compliance.
Where it stands out
- Automated image management and onboarding
- Proprietary lung image biomarkers (Lung8™, Air8™, Fibr8™, Glass8™, Vascul8™)
- Treatment response tracking
- Synthetic control arms for clinical trials
- Real-world data access
- GxP and 21 CFR Part 11 compliance
- Rapid site qualification
- Central image reads and clinical trial read-outs
Pricing
Pricing model: Contact for pricing
Questions
- What are Qureight's main products?
- Qureight offers three main products: global imaging CRO services with workflow tools and proprietary infrastructure for rapid site onboarding; AI-powered endpoints and analytics using proprietary deep-learning lung image biomarkers (Lung8™, Air8™, Fibr8™, Glass8™ and Vascul8™) for tracking treatment response and predicting disease progression; and data science products including synthetic control arms for clinical trials using access to some of the largest real-world datasets in IPF, PPF, PH and Bronchiectasis.
- What therapeutic areas does Qureight focus on?
- Qureight specializes in Interstitial Lung Diseases (including Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis), Pulmonary Hypertension, and Bronchiectasis. These are the company's current therapeutic areas where it provides imaging and biomarker solutions.
- How quickly can Qureight onboard imaging sites?
- Qureight can deliver qualified imaging sites in as little as 2 to 3 weeks after a study contract, using its proprietary infrastructure for rapid global trial site onboarding.
- What compliance standards does Qureight maintain?
- Qureight operates a management system certified to ISO 13485:2016 and ISO 27001:2022. The Qureight Platform is GxP and 21 CFR Part 11 compliant, ensuring regulatory compliance for clinical trial imaging.
- What are synthetic control arms and how does Qureight use them?
- Synthetic control arms are used in clinical trials to enable robust efficacy assessment in cases where placebo arms are impractical, unethical, or inefficient. Qureight uses its commercial access to some of the largest real-world datasets in respiratory disease to offer synthetic control arms as a data science product for biopharma companies.
Qureight has a free listing. The owner can unlock the full profile with a paid launch for $5:
- Founder story (locked)
- Milestones (locked)
- Demo video (locked)
- Dofollow website link (locked)